247 related articles for article (PubMed ID: 32011468)
1. Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: A systematic review and meta-analysis.
Zhou K; Zhao S; Guo W; Ding L
Medicine (Baltimore); 2020 Jan; 99(3):e18771. PubMed ID: 32011468
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib plus bevacizumab versus erlotinib alone in patients with
Deng W; Wang K; Jiang Y; Li D; Bao C; Luo J; Liu L; Huang B; Kong J
BMJ Open; 2022 Aug; 12(8):e062036. PubMed ID: 35985780
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.
Zhang S; Mao XD; Wang HT; Cai F; Xu J
BMJ Open; 2016 Jun; 6(6):e011714. PubMed ID: 27363819
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
Zhao B; Zhang W; Yu D; Xu J; Wei Y
Lung Cancer; 2018 Aug; 122():10-21. PubMed ID: 30032815
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H; Fukuhara T; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Gemma A; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M
Lancet Oncol; 2019 May; 20(5):625-635. PubMed ID: 30975627
[TBL] [Abstract][Full Text] [Related]
9. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Gridelli C; Rossi A; Ciardiello F; De Marinis F; Crinò L; Morabito A; Morgillo F; Montanino A; Daniele G; Piccirillo MC; Normanno N; Gallo C; Perrone F
Clin Lung Cancer; 2016 Sep; 17(5):461-465. PubMed ID: 27209164
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis.
Wu FZ; Song JJ; Zhao ZW; Huang XF; Mao JT; Tu JF; Chen MJ; Chen WQ; Fang SJ; Zheng LY; Fan XX
Math Biosci Eng; 2019 Aug; 16(6):7921-7933. PubMed ID: 31698647
[No Abstract] [Full Text] [Related]
11. Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials.
Li R; Li W; Zhang F; Li S
Eur J Med Res; 2023 Aug; 28(1):302. PubMed ID: 37635242
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of anti-angiogenic drugs combined with erlotinib in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized clinical trials.
Chen Z; Jiang S; Li X; Zhang J; Liu L; Li J; Cao P; Xin Y; Zhang L
Ann Palliat Med; 2021 Mar; 10(3):2687-2698. PubMed ID: 33548993
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.
Yamamoto N; Seto T; Nishio M; Goto K; Yamamoto N; Okamoto I; Yamanaka T; Tanaka M; Takahashi K; Fukuoka M
Lung Cancer; 2021 Jan; 151():20-24. PubMed ID: 33279874
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
15. Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.
Xu R; Shao H; Zhu J; Ju Q; Shi H
Medicine (Baltimore); 2019 Mar; 98(13):e14135. PubMed ID: 30921175
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
Takashina T; Asahina H; Oizumi S; Yamada N; Harada M; Takamura K; Yokouchi H; Harada T; Honjo O; Ogi T; Morikawa N; Kinoshita I; Honda R; Nakano K; Kanazawa K; Amano T; Dosaka-Akita H; Isobe H; Nishimura M;
Int J Clin Oncol; 2018 Dec; 23(6):1060-1069. PubMed ID: 30027464
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.
Zhou Q; Xu CR; Cheng Y; Liu YP; Chen GY; Cui JW; Yang N; Song Y; Li XL; Lu S; Zhou JY; Ma ZY; Yu SY; Huang C; Shu YQ; Wang Z; Yang JJ; Tu HY; Zhong WZ; Wu YL
Cancer Cell; 2021 Sep; 39(9):1279-1291.e3. PubMed ID: 34388377
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Pan G; Ke S; Zhao J
Target Oncol; 2013 Jun; 8(2):107-16. PubMed ID: 23516098
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
Rosell R; Dafni U; Felip E; Curioni-Fontecedro A; Gautschi O; Peters S; Massutí B; Palmero R; Aix SP; Carcereny E; Früh M; Pless M; Popat S; Kotsakis A; Cuffe S; Bidoli P; Favaretto A; Froesch P; Reguart N; Puente J; Coate L; Barlesi F; Rauch D; Thomas M; Camps C; Gómez-Codina J; Majem M; Porta R; Shah R; Hanrahan E; Kammler R; Ruepp B; Rabaglio M; Kassapian M; Karachaliou N; Tam R; Shames DS; Molina-Vila MA; Stahel RA;
Lancet Respir Med; 2017 May; 5(5):435-444. PubMed ID: 28408243
[TBL] [Abstract][Full Text] [Related]
20. A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.
Hirano S; Naka G; Takeda Y; Iikura M; Hayama N; Yanagisawa A; Amano H; Nakamura M; Nakamura S; Tabeta H; Sugiyama H
Chin Clin Oncol; 2016 Dec; 5(6):77. PubMed ID: 28061541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]